MitoQ and Ischemic Conditioning To Assess Vascular Health Outcomes
MitoQ and Ischemic Conditioning To Assess Vascular Health Outcomes (MITO Study)
Medical College of Wisconsin
30 participants
Jul 22, 2025
INTERVENTIONAL
Conditions
Summary
Stroke survivors have compromised vascular function which may contribute to secondary stroke risk, cardiovascular disease, and may limit their exercise tolerance. Preliminary data shows a single bout of ischemic conditioning or oral ingestion of an over-the-counter antioxidant supplement called MitoQ may improve vascular function and muscle activity in individuals post-stroke.
Eligibility
Inclusion Criteria4
- years of age
- Cortical or sub-cortical stroke ≥ 6 months ago with residual hemiparesis
- Able to give informed consent and follow 2-step command.
- English Speaking
Exclusion Criteria10
- Unable to stand from chair without physical assistance from another person (able to use assistive device).
- History of blood clots in the extremities or any condition in which compression of the thigh or transient ischemia is contraindicated (i.e., wounds in the leg).
- Chronic lasting symptoms (\> 6 months) of severe COVID-19 (i.e., hospitalization)
- History of head trauma or concussion within the past 6 months
- Comorbid neurological disorder
- Peripheral vascular disease
- Myocardial infarction or arrhythmia in the previous year
- Resting SBP ≥180 mmHg or DBP ≥ 100 mmHg
- Pregnant or breastfeeding.
- Other significant medical condition likely to influence study or jeopardize safety as assessed by the Primary Investigator
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The cuff will be placed around the proximal, non-affected thigh and inflated for 5 minutes in a supine or semi-reclined position, then released for a 5-minute recovery period. Five cycles of inflation and recovery will be performed (45 minutes total).These inflations will be done using a cuff similar to what is used for taking blood pressure.
MitoQ is an over the counter supplement that increases delivery to the mitochondria. Similar to studies performed in middle age/older adults and individuals with peripheral arterial disease, we will administer 1 single oral dose of 80mg of MitoQ or a placebo pill. As MitoQ reaches peak concentrations at \~40 to 60 minutes after ingestion, we will wait 45 minutes (time matched to Ischemic conditioning).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06930638